Answers are grounded in this paper and cite their sources.
Dear Editor, Pustulotic arthro-osteitis (PAO) is a refractory condition associated with palmoplantar pustulosis (PPP), which affects the sternocostoclavicular joints in over 80% of the cases. A new biologic, guselkumab, is shown to be effective for not only PPP but also PAO in a phase 3 study. However, its effect on joint manifestation other than anterior chest wall areas is yet unknown in a real-world setting. Herein, a case of PPP with spondylitis-type PAO with 20-years' duration, which dramatically improved after a single use of guselkumab is described. A 66-year-old female with PPP and PAO was referred to our department. She was suffering from PPP and severe joint pain for 20 years, which appeared almost simultaneously, and had been treated without satisfactory results. She was a smoker (20 cigarettes a day for 25 years), but quit smoking soon after she was diagnosed as having PPP. Dental treatment was already completed, and examination for focal infections such as tonsillitis was normal. Physical examination showed palmoplantar erythema with scales as well as a small number of pustules and vesiculopustules (Figure 1A). Scaly erythemas were scattered on the lower legs. A biopsy specimen from the plantar
No takes yet. Share an insight, caveat, or question.
Toshiyuki Yamamoto (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: